Study on the mechanism of coronary microcirculation disorder after PCI for coronary heart disease and the clinical effect of glaxinning intervention

Study on the therapeutic effect of Gelanxinning soft capsule on patients with coronary artery microcirculation disorders after PCI for coronary heart disease

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300074239

Enrollment

Unknown

Registered

2023-08-02

Start date

2023-01-10

Completion date

Unknown

Last updated

2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

Treatment group:Routine oral medication treatment after PCI +2 capsules/dose of granxinning tid,

Control group:Routine oral medication treatment after PCI

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-75 years old, regardless of gender, (2) Clear diagnosis of coronary heart disease and successful PCI to open the epicardial coronary artery, with residual stenosis in each branch of the coronary artery narrow diameter<50%, (3) Regular oral medication treatment (aspirin 100mg qd, clopidogrel 75mg qd, atorvastatin calcium 20mg qd) 1 month after PCI, still with angina pectoris, exertional chest tightness, shortness of breath, or other atypical heart disease symptoms related to muscle ischemia, (4) CAG reexamination indicates that the diameter of each epicardial coronary artery stenosis is less than 50%, (5) Sign an informed consent form and voluntarily participate in this study, (6) Successfully completed temperature pressure guide wire measurement IMR.

Exclusion criteria

Exclusion criteria: (1) Suffering from chronic pulmonary heart disease, dilated cardiomyopathy, and hypertrophic cardiomyopathy, (2) Diseases that have a significant impact on inflammation related indicators, such as upper respiratory tract infections, (3) Severe liver dysfunction (ALT or AST>200U/l), renal dysfunction (GFR<60ml/min), (4) Cardiac ultrasound examination indicates that the left ventricular ejection fraction is less than 50%, (5) Severe arrhythmia that may cause hemodynamic instability, (6) Contraindications or allergies to adenosine triphosphate intravenous injection, (7) Poor medication adherence, inability to take medication on time, and timely follow-up visits, (8) Combined with malignant tumors and other diseases, with a life expectancy of less than 1 year.

Design outcomes

Primary

Measure	Time frame
Seattle Chest Pain Scale; SIRT1, NLRP3, IL-18, LECT2, Irisin, sST2, TNFRSF18 and other inflammatory indicators;SDC-1, SDC-4, HS, HA, GDF-15, MDA and other oxidative stress related indicators;	—

Secondary

Measure	Time frame
Myocardial remodeling indicators;	—

Countries

China

Contacts

Public ContactCheng Gong

Shaanxi Provincial People's Hospital

xianchenggong@163.com+86 186 2952 9996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026